Display options
Share it on

Oncoimmunology. 2014 Jan 01;3(3):e28246. doi: 10.4161/onci.28246. Epub 2014 Mar 17.

slanDCs in carcinoma-draining lymph nodes.

Oncoimmunology

William Vermi, Silvia Lonardi, Mattia Bugatti, Federica Calzetti, Alessandra Micheletti, Marco A Cassatella

Affiliations

  1. Department of Molecular and Translational Medicine; Section of Pathology; University of Brescia; Brescia, Italy ; Department of Pathology and Immunology; Washington University School of Medicine; Saint Louis, MO USA.
  2. Department of Molecular and Translational Medicine; Section of Pathology; University of Brescia; Brescia, Italy.
  3. Department of Pathology and Diagnostics; Section of General Pathology; University of Verona; Verona, Italy.

PMID: 24843832 PMCID: PMC4022602 DOI: 10.4161/onci.28246

Abstract

Dendritic cells (DCs) are known to initiate adaptive immune responses against malignant cells. However, the role in anticancer immunosurveillance of 6-sulfo LacNAc-expressing DCs (slanDCs), a distinct population of circulating and tissue-resident pro-inflammatory DCs, is unclear. We have recently demonstrated the involvement of slanDCs in nodal immune responses against carcinoma cells.

Keywords: carcinoma; slanDCs; tumor-draining lymph nodes

References

  1. Science. 2011 Mar 25;331(6024):1565-70 - PubMed
  2. Nat Commun. 2014;5:3029 - PubMed
  3. Immunity. 2002 Sep;17(3):289-301 - PubMed
  4. Blood. 2010 Oct 21;116(16):e74-80 - PubMed
  5. J Allergy Clin Immunol. 2011 Mar;127(3):787-94.e1-9 - PubMed
  6. Blood. 2011 Feb 3;117(5):1677-86 - PubMed
  7. Eur J Immunol. 1998 Dec;28(12):4084-93 - PubMed
  8. J Immunol. 2000 Dec 1;165(11):6037-46 - PubMed
  9. Immunity. 2006 Jun;24(6):767-777 - PubMed
  10. Blood. 2007 Jun 15;109(12):5276-85 - PubMed

Publication Types